Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Children's Qingfei Oral Liquid (Xiao'er Qingfei Koufuye) is a Traditional Chinese Medicine (TCM) formulation developed for pediatric respiratory care. It is primarily indicated for the treatment of bronchial asthma and acute upper respiratory tract infections in children. The formulation is designed to clear heat from the lungs, resolve phlegm, and alleviate cough and wheezing. It is currently being evaluated in clinical studies, such as those conducted by The First Teaching Hospital of Tianjin University of Chinese Medicine, to assess its efficacy in preventing and shortening acute bronchial asthma attacks triggered by viral infections. The liquid typically contains a synergistic blend of herbal extracts, including Ephedra and Scutellaria, which provide bronchodilatory and anti-inflammatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Children's Qingfei Oral Liquid.